cDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product by Marchuk, Douglas A. et al.
GENOMICS 11, 931-940 (1991) 
cDNA Cloning of the Type 1 Neurofibromatosis Gene: 
Complete Sequence of the NH Gene Product 
DOUGLAS A. MARCHUK, ANN M. SAULINO, ROXANNE TAVAKKOL, MANJU SWAROOP, 
MARGARET R. WALLACE, LONE B. ANDERSEN, ANNA L. MITCHELL, 
DAVID H. GUTMANN, MARK BOGUSKI,” AND FRANCIS S. COLLINS 
Departments of Human Genetics and Internal Medicine and the Howard Hughes Medical Institute, The University of Michigan 
Medical Center, Ann Arbor, Michigan 48109; and *National Center for Biotechnology Information, 
National Library of Medicine, National Institutes of Health, Bethesda, Maryland 20894 
ReceivedJune 26, 1991;revisedJuly26, 1991 
Von Recklinghausen neuroflbromatosis, or type 1 neuro- 
flbromatosis (NFl), is a common autosomal dominant dis- 
order characterized by abnormalities in multiple tissues de- 
rived from the embryonic neural crest. Portions of the gene 
have been recently identiiled by positional cloning, and se- 
quence analysis has shown homology to the GTPase acti- 
vating protein (GAP) family. In this report we present the 
results of an extensive cDNA walk resulting in the cloning 
of the complete coding region of the NFZ transcript. Analy- 
sis of the sequences reveals an open reading frame of 2818 
amino acids, although alternatively spliced products may 
code for different protein isoforms. The gene extends for 
approximately 300 kb on chromosome 17, with its pro- 
moter in a CpG-rich island. o 1~1 ACE~~ZGC POW, I~~. 
INTRODUCTION 
Von Recklinghausen neurofibromatosis (NFl) is 
one of the most common inherited disorders in hu- 
mans, with an incidence of about 1 in 3000, and af- 
fecting all ethnic groups (Crowe et al., 1956; Riccardi, 
1981; Riccardi and Eichner, 1986). The spontaneous 
mutation rate is very high, with 3040% of cases being 
new mutations. This leads to a calculated mutation 
rate of l/10,000, which is about loo-fold higher than 
the usual mutation rate for a single locus. 
The clinical features of the disorder can be quite 
variable, even among affected family members, indi- 
cating that factors other than the specific mutation 
inherited must play a role in the disease phenotype. 
Diagnostic criteria for NFl have been established 
(Stumpf et al., 1987) and with careful examination it 
is rare to identify an obligate carrier who does not 
meet these criteria (Riccardi and Lewis, 1988). Diag- 
nostic features include cafe-au-lait spots, Lisch nod- 
ules, and neurofibromas in the majority of gene car- 
riers. Some individuals may also have learning dis- 
orders, more deeply placed plexiform neurofibromas, 
seizures, or skeletal abnormalities. The risk of malig- 
nancy is also increased, especially for optic glioma, 
neurofibrosarcoma, and brain tumors. 
Recently, a gene was identified by positional clon- 
ing showing mutations in individuals affected with 
NFl (Cawthon et CLZ., 1990a; Viskochil et al., 1990; 
Wallace et al., 1990). Further cloning and partial se- 
quence analysis demonstrated that the gene product 
contains a domain showing approximately 30% simi- 
larity to the catalytic domains of yeast IRA1 and 
IRA2 proteins and the mammalian GTPase activat- 
ing protein (GAP) (Xu et al., 1990a). GAP is a cyto- 
solic protein that catalyzes the conversion of active 
GTP-bound ras p21 to the inactive GDP-bound form 
(Trahey and McCormick, 1987; Trahey et al., 1988; 
Vogel et uZ., 1988). The IRA genes of Saccharomyces 
cerevisiae encode negative regulators of the yeast RAS 
genes that are homologs of mammalian GAP (Tanaka 
et uZ., 1989, 1990, 1991). It was subsequently shown 
that the GAP-related domain of the NFl gene prod- 
uct can also interact with human and yeast ~(2s p21 to 
down-regulate its activity (Ballester et cd., 1990; Mar- 
tin et UC, 1990; Xu et al., 199Ob). 
Previous reports of cDNA cloning of NFl were 
based on incomplete fragments of the transcript, 
which is approximately 13 kb by Northern blotting 
(Wallace et uZ., 1990). In this report we present the 
complete amino acid sequence of the NFl gene prod- 
uct as deduced from cDNA clones containing the en- 
tire coding region of the gene. The location and extent 
of the NFl gene on the genomic map of chromosome 
17 is also determined. 
MATERIALS AND METHODS 
Isolation of NFl cDNA Clones 
Five different cDNA libraries were used in the 
cDNA walk. A human fetal brain cDNA library, 
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FIG. 1. A schematic diagram representing the cDNA walk in the NFl gene. The open reading frame is represented by the wide region 
bordered by the ATG and TGA codons, and the extent of the GAP-related domain used in complementation studies (Ref. (3)) is indicated 
Clones are listed below the schematic of the transcript; straight lines represent authentic transcript and jagged lines represent cocloning 
events. EcoRI sites are represented by vertical lines. Clones B3A and P5 have previously been described (Ref. (62)). Clones AE25, KE-2, and 
GE-2 were isolated from an endothelial cell cDNA library (Ref. (21)). Clones HFGB, FBBD, HF’IB, EF3, EF8, FFl, EF2, FF13, and HFBA 
were isolated from a fetal brain cDNA library (Stratagene, No. 936206). Clone CAT2 was isolated from the same library by PCR from total 
phage lysate from the library (Ref. (3)). Clone AM20 was isolated from a human brain (medulla) cDNA library (Clontech, No. HLlOSla), 
and clone GMSA was isolated from a fetal muscle cDNA library (Ref. (30)). 
oligo(dT) and random primed, was obtained from 
Stratagene, La Jolla, CA (No. 936206). Adult human 
brain (occipital pole and medulla) cDNA libraries, 
random and oligo(dT) primed, were obtained from 
Clontech, Palo Alto, CA (No’s. HLlOSla and 
HL1089). An oligo d(T) primed human fetal muscle 
library is described in Koenig et ~2. (1987), and a ran- 
dom primed endothelial cell library is described in 
Ginsburg et al. (1985). Typically, 500,000 plaques of 
each library were plated and screened (Benton and 
Davis, 1977) using an aqueous hybridization consist- 
ing of 6X SSC, 2~ Denhardt’s solution, 1 mM EDTA, 
and 0.5% SDS at 65°C. Washes were in 2X, 1X, and if 
needed, 0.2~ SSC, 0.1% SDS at 65°C. Positive 
plaques were purified, and subcloned into Bluescript 
plasmid (Stratagene) or rescued as plasmid per X ZAP 
instructions (Stratagene) in the case of the fetal brain 
library. 
Sequence Analysis of Clones 
Double-stranded sequencing of plasmid clones was 
performed using Sequenase Version 2.0 (U.S. Bio- 
chemicals, Cleveland, OH) per instructions. Sequence 
compilation was aided by the IBI/Pustell sequence 
analysis program package (International Biotechno- 
logies, Inc., New Haven, CT). Analysis of the amino 
acid sequence was performed with the University of 
Wisconsin Genetics Computer Group protein analy- 
sis package (Devereux et aZ., 1984). 
Primer Extension 
Total RNA was isolated from fresh human brain 
(frontal lobe) and melanoma cell line SK-MEL-23 
(Carey et al., 1976) as described in Sambrook et al. 
(1989). Polyadenylated RNA was isolated from mela- 
noma total RNA using the FastTrack mRNA isola- 
tion kit (Invitrogen Corp., San Diego, CA). For 
primer extension, an oligomer (5’ AGAGGCAAGGA- 
GAGGGTCTGTG) was synthesized, kinased with 
32P and extended off of brain (total) or melanoma 
(poiy(A)+) RNA (Boorstein and Craig, 1989). Prod- 
ucts were analyzed on a 6% denaturing polyacryl- 
amide gel. 
RESULTS 
Figure 1 shows a cDNA walk extending from the 3’ 
end of the NFl gene. The initial clones P5 and B3A 
were isolated as previously described (Wallace et al., 
1990). Since the NFl transcript has been shown to be 
ubiquitously expressed (Buchberg et aZ., 1990; Wal- 
lace et al., 1990), cDNA walking proceeded in multiple 
cDNA libraries in order to maximize chances of find- 
ing positives. Library sources included fetal muscle, 



















251 DLVDGFAESTKRKAAVWPLQI ILLILCPEIIQDISKDVVD 
1081 GAAAACMCATGMTMGMGTTATTTCTGGACAGTCTACG~GCTCTTGCTGGCCATGGAGGMGTAGGCAGCTGACAG~GTGCTGCMTTGCCTGTGTC~CTGTGT~GCA 
291 ENNMNKKLFLDSLRKALAGHGGSRQLTESAAIACbKLCKA 
1201 AGTACTTACATC 1212 
331 S T  Y I 
FIG. 2. cDNA sequence of the 5’portion of the NFl transcript. The sequence listed has not been previously published and ends where the 
previously published sequence begins (Ref. (65)). The sequence was compiled from clones KE-2, GE-2, GMSA, EF2, FF13, and HFBA. Both 
strands were sequenced at least once to complete the sequence. The nucleotide and deduced amino acid sequence are numbered along the left 
column. The start codon is underlined, and the upstream in-frame stop codon is boxed. The position of the oligonucleotide used for primer 
extension (Fig. 3) is shown by an arrow. The position of the first intron is indicated by a triangle. 
fetal brain, adult brain (occipital pole and medulla), 
and endothelial cells. Walks proceeded sequentially 
by isolation of positive phage clones using the most 5’ 
cDNA insert. The positive clones were characterized 
by restriction mapping using EcoRI and Southern 
blot analysis using previously isolated inserts. The 
phage clones were subcloned into Bluescript (Strata- 
gene) and the ends were sequenced to anchor the po- 
sition of the clones to the transcript map. The cycle 
was repeated for each walk. Underrepresented regions 
in any given library were overcome by crossing into 
another library. The entire transcript as represented 
in the clones was sequenced multiple times and both 
strands were sequenced at least once for all previously 
unpublished sequence. 
As the cDNA walk neared completion, a very GC- 
rich region of the transcript that contained an abnor- 
mally high concentration of the dinucleotide CpG, as 
well as rare cutting restriction endonuclease sites 
EogI, NurI, and SucII, was encountered at the 5’ end. 
These sites had been previously placed on the pulsed- 
field map of this region using the linking clone 17Ll 
(Fountain et al., 1989a). This clone was isolated from 
a Not1 linking library constructed from DNA from 
flow-sorted chromosome 17 (Wallace et al., 1989), and 
contains the sequences flanking both sides of a geno- 
mic Not1 site. This probe was originally used to detect 
a translocation breakpoint within the NFl gene, 
which narrowed the search for the gene to a region of 
only about 300 kb (Fountain et al., 198913). Southern 
blots using the CpG-rich cDNAs as probes against 
17Ll demonstrated that the most 5’ sequences ob- 
tained were indeed located in the centromeric half of 
this clone (17LlB), approximately 300 kb from the 3’ 
stop codon (data not shown). 
The most 5’ cDNA clone, KR-2, isolated from the 
endothelial cell cDNA library, contained an in-frame 
stop codon (Fig. 2). Downstream from this stop co- 
don, the first ATG fits the rules for a proper transla- 
tional start (Kozak, 1986). Overlapping sequences 
have been found in cDNA clones from three different 
tissues (fetal muscle, fetal brain, and endothelial 
cells). We propose that this ATG codon represents 
the authentic start codon, giving the protein a total of 
2818 amino acids with a predicted molecular weight of 
327 kDa. 
To determine whether a substantial portion of the 
5’ end of this transcript remained uncloned, a primer 
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FIG. 3. Primer extension off of human brain (frontal lobe) to- 
tal RNA and melanoma cell line SK-MEL-23 poly(A)+ RNA. The 
primer was chosen upstream from the proposed start codon at a 
position shown in Fig. 2. A group of four major products are seen in 
the brain RNA ranging in size from approximately 380 to 410 
bases. A second site is seen at about 300 base from the primer. The 
melanoma cell line shows only the 410 and 400 base products, even 
after longer exposure. 
extension was performed using human brain (frontal 
lobe) total RNA and melanoma cell line SK-MEL-23 
poly(A)+ RNA. A reverse transcription primer was 
chosen that was 5’, of the proposed start codon. Figure 
3 shows the result of this analysis. A series of four 
bands ranging in size from 380 to 410 bp is seen in the 
primer extension from brain RNA. A second promi- 
nent band of 300 bp is also seen. Primer extension 
from the melanoma RNA shows the top two bands at 
400 and 410 bp, but does not show the lower band at 
300 bp. We have cloned and sequenced 119 bp from 
the 5’ position of this primer, indicating that at most 
only 291 bp remains uncloned. Within the cloned se- 
quence lies the start codon and upstream in-frame 
stop codon. These results indicate that the entire cod- 
ing region of the transcript has been cloned and se- 
quenced. 
Sequencing of the proximal half of the Not1 linking 
clone 1’7Ll (17LlB) demonstrated that the 5’ cDNA 
sequences from nucleotide 1 to 270 exist in this region 
of the genome as a single continuous exon. We con- 
clude from this that exon 1 of this transcript contains 
a majority of sequence that is 5’ untranslated. If an- 
other exon is spliced in upstream from this, it would 
consist entirely of noncoding sequence. We also con- 
clude that the transcriptional start site and the pro- 
moter region probably exist in the half linking clone 
17LlB. 
In the course of screening for cDNA clones that 
extended beyond our most 5’ clone, two alternative 
sequences were discovered. Both begin at position 
270, the position of the first splice junction, and are 
represented by single cDNA clones from a fetal brain 
cDNA library. Further analysis of these clones has 
revealed that neither represent authentic NFl 
mRNA. One sequence appeared to be derived from an 
unspliced message, as it contains a perfect splice-ac- 
ceptor consensus sequence, a pyrimidine stretch of 20 
bases, and a lariat formation consensus sequence 
(Sharp, 1987). This has been confirmed by designing 
primers that extend across the splice junction and by 
showing that these primers will amplify the expected 
fragment using genomic DNA as a template (data not 
shown). A second unusual clone diverges at the exact 
same position, yet has a different sequence. This 
clone has been shown to be the result of a rare trans- 
splicing event since the new sequence does not map to 
chromosome 17. We therefore conclude that there is 
no evidence for alternative splicing at the extreme 5’ 
end of the gene. 
We have been unable to characterize the 3’ end of 
the NFl transcript, as a poly(A) tail has not been 
found in any cDNA clone. Our previous sequence anal- 
ysis (Wallace et aZ., 1990) has shown the proper posi- 
tion of the stop codon. Downstream from this the se- 
quence is very A rich, with some regions that are capa- 
ble of priming with oligo(dT) during construction of 
the cDNA libraries. The NFl transcript has been es- 
timated to be 13 kb by its migration on a Northern 
blot (Wallace et al., 1990). To date we have cloned and 
sequenced 9 kb of this message. The primer extension 
results (Fig. 3) indicate that the majority of uncloned 
sequence from this transcript must arise from a long 
(approximately 4 kb) 3’ untranslated region. Alterna- 
tively, our estimates of transcript size may be incor- 
rect, as size estimates in this range of Northern blot- 
ting are difficult. 
Two alternatively processed forms of this primary 
transcript have been discovered. A 54-bp insertion 
coding for an additional 18 amino acids near the 3’ 
end of the transcript has been described previously 
(Cawthon et al., 1990). A 63-bp insertion coding for an 
additional 21 amino acids within one of the most con- 
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1 MAAHRPV!ZkiV QAWSRFDEQ LPIKTGQ4JNT HTKVSTEHNK ECLINISKYK FSLVISGLTT 1-1 ?GEAAEiKH LY LSQLIILDTL EKCLAGQPKD 
101 TMRLDETMLV KQLLPEICHF LHTCREGNQH AAELRNSASG VLFSLSCNNF NAVFSRISTR LQELTVCSED NVDVHDIELL QYINVDCAKL KRLLKETAFK 
201 FKALKXVAQL AVINSLEKAF -PDE Fl'KLYQIPQT DMAECAMLF DLVXFAEST KRKAAVWPLQ IILLILCPEI IQDISKDWD ENNMNKKLFL 
301 DSLRKALAGH GGSRQLTESA AIACVKLCKA STYINWEDNS VIFLLVQSMV VDLKNLLFNP SKPFSRGSQP ADVDLMIDCL VSCFRISPHN NQHFKICLAQ 
401 NSPSTFHYVL VNSLHRIITN SALmFKID AVYCHSVELR NHFGETLHKA VQGCGAHPAI RMAPSLTFKE KVTSLKFKEK FTDLETRSYK YLLLSMVKLI 
501 HADPKLLLCN PRKCGPETQG STAELITGLV QLVPQSHMPE IAQEJbMEALL VLHQLDSIDL WNPDAPVETF WEISSQMLFY IC2SHQI-l LSSTEILKWL 
601 REILICRNKF LLKNKQADRS SCHFLLFYGV GCDIPSSGNT SQMSMDHEEL LRTPGASLRK GKGNSSMDSA AGCSGTPPIC RQAQTKLEVA LYMFLWNPDT 
701 EAVLVAMSCF RHLCEEADIR CGVDEVSVHN LLPNYNTFNE FASVSNMMST GRAALQKRVM ALLRRIEHPT AGNTEAWEDT HAKWEQATKL ILNYPKAKJUZ 
801 DGQllAESLliK TXVI@~HV SGGGSIDLSD TDSLQEZWINM TGFLCALGGV CLQQRSNSGL ATYSPPMGPV SER-ISV MSSEGNADTP VSKR-lDRLLS 
901 LNVCNHEKVG LQIRTNVKDL VGLELSPALY PMLFNKLKNT ISKFFDSQGQ VLLTDTNTQF VEQTIAIMKN LLDNHTEGSS EHLGQASIET MMLNLVRYVR 
1001 VLGNMVHAIQ IKTKLCQLVE BDDLS FCQFiMKFRNK MVFXLTDWVM GTSNQAADDD VKCLTRDLDQ ASMEAWSLL AGLPLQPEEG DGVELMEAKS 
1101 QLFLKYFI'LF MNLLNDCSEV EDESAQTGGR KRGMSRRLAS LRHCTVLAMS NLLNANVDSG LMHSIGLGYH KDLQTRATFM EVLTKILQQG TEFDTLAETV 
1201 LADRFFRLVE Lk-R442D@ZE LPIAMALANV VPCSQrlDELA RVLVTLFDSR HLLYQLL!dNM FS&ELADS MQTLFk3KS.L ASKIMPFClXjVYGA%!LQKL 
w 
1301 LDPLLRIVIT SSBJQHVSFE VDPTRLEPSE SLEENQRNLL QMTEkFFHAI ISSSSEFkQ LRSVCHCLYQ-WSQRFiQNS I@S'GSd;, ;(FIN&& 
1401 YSAGIL@GCP PPRi$RGLKL MSlk.&I~;HVLFTKEEHM RPFNDFVKSN FDAARRFFLD IASDCFTSDA VNHSLSFISD GNVLALHRLL WNNQEKIGQY 
1501 LSSNRDHKAV GRRPFDKMAT LLAYLGPPEH KPVADTHWSS LNLTSSKFEE FMI'RHQVHEK EEFKALKTLS IFYQAGTSKA GNPIFYYVAR RFKTGQINGD 
1601 LLIYHVLLTL KPYYAKPYFJ WDLTHTGPS NRFKTDFLSK WFWFPGFAY DNVSAVYIYN CNSWVREYTK YHERLLTGLK GSKRLVFIDC PGKLAEHIEH 
1701 EQQKLPAATL ALEEDLKVFH NALKUHKDT KVSIKVGSTA VQVTSAERTK VLGQSVFLND IYYASEIEEI CLVDENQFTL TIANQGTPLT FMHQECEAIV 
1801 QSIIHIRTRW ELSQPDSIFQ H'MIRPKDVP GTLLNIALLN LGSSDPSLRS AAYNLLCALT CTFNLKIEGQ LLETSGLCIP ANXTLFIVSI SKTLAANEPH 
1901 LTLEFLEECI SGFSKSSIEL KHLCLmP WLSNLVRFCK HNDDAKRQRV TAILDKLITM TINEKQMYPS IQAKIWGSLG QITDLLDWL DSFIKTSATG 
2001 GLGSIKAEVM ADTAVALASG NVKLVSSKVI GRMCKIIDKT CLSFTFTLEQ HWDIAIL ARYMLMLSFN NSLDVAAHLP YLFHWTFLV ATGPLSLRAS 
2101 THGLVINIIH SLCXSQLHF SEETKQVLRL SLTEFSLPKF YLLFGISKVK SAAVIAFRSS YRDRSFSPGS YERETFALTS LETVTEALLE IMFXXRDIP 
2201 TCKWLME LAQRFAFQYN PSLQF'RALW FGCISWH GQIKQIIRIL SKALESCLKG PDTYNSQVLI EATVIALTKL QPLLNKDSPL HKALEWVAVA 
2301 VLQLDEVNLY SAGTALLEQN LHTLDSLRIF NDKSPEEVFM AIRNPLEWHC KQMDHFVGLN FNSNFNFALV GHLLKGYRHP SPAIVARTVR ILHTLLTLVN 
2401 KHRNCDKFEV NTQSVAYLAA LLTVSEEVRS RCSLKHRKSL LLTDISNENV PMMYPIHHG DPSYRTLKET QEWSSPKGSE GYLAATYFTV GQTSPRARKS 
2501 MSLLWZQPSQ AIVZKKLLGTR KSFDHLISDT KAPKRQEMES GITTPPnlRR VAFZDYEMET QRISSSQQHP HLRKVSVSES NVLLDEEVLT DPKIQALLLT 
2601 VLATLVKYTT DEFDQRILYE YLAEASWFP KVFPWHNLL DSKINTLLSL CQDPNLLNPI HGIVQSWYH EESPPQYQTS YL.QSFGFNGL WRFAGPFSKQ 
2701 TQIPDYAELI VKFLDALIDT YLPGIDEETS EESLLTPTSP YPPALQSQLS ITANLNLSNS MTSLATSQHS 24 IDKENVEL SFTTGHCNSG RTRHGSASQV 
2801 QKQRSAGSFK_ mIKKIV 
FIG. 4. The complete amino acid sequence of the NFl gene product. The sequence was deduced from the open reading frame of 
sequenced clones from a cDNA walk. Boxed regions correspond to the most statistically significant regions of similarity among the GAP 
family of proteins with the invariant residues marked with stars (Ref. (63)), some of which appear to be functionally significant in a yeast 
complementation assay (D. Gutmann, unpublished observations). Residues underlined with a single line are potential CAMP-dependent 
protein kinase recognition sites (Ref. (22)). Residues that are double underlined represent a potential tyrosine phosphorylation recognition 
sequence (Ref. (15)). The position of a 21-amino-acid insertion (ATCHSLLNKATVKEKKENKKS) representing an alternatively spliced 
product is shown with a dark triangle (Andersen et al., manuscript in preparation.) The position of an l&amino-acid insertion (ASLPCSN- 
SAVFMQLFPHQ) representing an alternatively spliced product is shown by a open triangle (Ref. (64)). We found three regions of our 
nucleotide sequence at variance with previously published sequence (Ref. (64)), two resulting in changes in the amino acid sequence. Residue 
number 496 in our clones shows an ATG methionine codon rather than an ATA isoleucine codon. Another sequence variation at residue 
1183 shows an CTG leucine codon rather than the previously published CTC. Our clones also lacked an extra CAT histidine codon after 
residue number 1555. The latter two changes noted agree with those of Martin et al. (32), from their sequence of a PCR clone of the 
GAP-related domain region. 
served regions of the GAP-related domain has been 
discovered (Fig. 4; Andersen et al., manuscript in prep- 
aration). The significance of this insertion to the ras 
GTPase activation will be discussed elsewhere. 
Figure 4 shows the complete amino acid sequence of 
the primary NFl transcript. Boxed areas indicate the 
three blocks of homology most conserved between the 
GAP family of proteins (Wang et al., 1991). The posi- 
tions of the alternatively spliced exons,and their se- 
quence are shown. There are no SH2 or SH3 domains 
(src homology domains), which are present in GAP 
(Koch et aZ., 1991). The protein shows no apparent 
membrane-spanning region and is predicted to be cy- 
tosolic by discriminant analysis (Klein et al., 1985). A 
potential leucine zipper is present beginning at amino 
acid residue 1834, but this region is not predicted to be 
in an a-helical conformation due to the presence of a 
proline in the middle of the repeat. Six potential 
CAMP-dependent protein kinase phosphorylation 
sites and a single potential tyrosine phosphorylation 
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FIG. 5. Extent of the NFl transcript on the genomic map of chromosome 17. The data were generated by mapping cDNAs against the 
pulsed-field restriction map of the region (Ref. (19)). Not1 sites representing the positions of undermethylated CpG islands in genomic DNA 
are shown with a boxed N. The 5’ end of the transcript begins in the centromeric half of the Not1 linking clone 17LlB (Refs. (19,20,61)). It 
extends through the position of a t(1;17) NFl translocation breakpoint (Refs. (20,37)) and beyond the position of a t(17;22) NFl transloca- 
tion breakpoint (Ref. (37)). The transcript ends before the second CpG island. The gene therefore extends a maximum of 300 kb. Three other 
transcripts are embedded within a single intron and are transcribed off the complementary strand (D. Marchuk, unpublished observations; 
Refs. (64,65)). The three genes are EVISA (Refs. (38,13)), EVIQB (Ref. (14)), and OMgp (Refs. (34,59)). 
site are present. The sequence shows no significant 
homology to the recently described &r-related GAP 
family, which includes n-chimaerin, and GAPrh” 
(Diekmann et al., 1991) and possibly the ~85 of bovine 
brain phosphatidylinositol 3-kinase (Otsu et aZ., 
1991). There is also no homology to the recently de- 
scribed raplGAP (Rubinfeld et ‘al., 1991). 
The size of the NFl gene has been determined by 
mapping cDNA clones back to the pulsed-field restric- 
tion map of the region (Fountain et al., 1989a). The 5’ 
end is just beyond the Not1 site within the linking 
clone 17LlB, the first intron beginning 81 bp centro- 
merit to the Not1 site. The most 3’ clone we have 
isolated does not extend beyond the Not1 site defining 
the next CpG island, and defines a maximum gene 
size of approximately 300 kb (Fig. 5). This assumes 
that the remainder of the 3’ untranslated region yet 
uncloned exists in a single exon. We have not charac- 
terized all of the intron-exon borders of the gene, but 
would estimate by the number of bands on a genomic 
Southern blot that it contains in excess of 30 exons. 
The three previously described embedded genes 
(EVI2A, EVIBB, and OMgp) are transcribed from the 
opposite strand and are contained within a single in- 
tron (D. Marchuk, unpublished observations; Xu et 
al., 1990a). 
DISCUSSION 
Initial partial sequences of the 3’ end of the NFl 
gene (Cawthon et al., 1990a; Wallace et al., 1990) re- 
vealed very little in the way of sequence homologies 
that could provide a clue to the function of the gene 
product. Further cloning and sequence analysis 
TABLE 1 
Results of Database Searching with Individual NFlGRP Domains 
Query sequence Related sequence Karlin score p-value No. of segments matched 
N-terminal domain Yeast IRA2 66 0.0011 10 
Yeast IRA1 72 0.12 1 
GAP-related domain Bovine GAP 81 2.9 x lo-l4 3 
Yeast IRA2 120 6.5 x lo-l3 3 
Yeast IRA1 112 8.2 x lo-O8 3 
C-terminal domain Yeast IRA2 92 7.1 x lo-” 2 
Yeast IRA1 80 8.5 x lo-“7 2 
Note. The BLASTP program (Ref. (2)) was used to search a composite database consisting of all nonidentical protein sequences from the 
following databases: NBRF/PIR (release 2&O), SWISS-PROT (release 18.0) GenPept (release 64.3), GenPept (daily update, 6/20/91), and 
NCBI’s GenInfo Backbone (prerelease version 6/20/91). At the time of submission this composite database contained 14,884,150 residues in 
55,571 sequences. The BLASTP program was used with default parameters except that the PAM250 matrix was used for scoring. Entries in 
the table represent a summary of the significant results. The Karlin scores and p-values were automatically computed according to Karlin 
and Altschuf (26). The Karlin score given represents the highest-scoring segment and the p-value is that of the most significant segment 
(when multiple, nonoverlapping matching segments were identified). Thus, thep-values indicate how surprising it is to find such similarities 
in a sequence collection of this size. Significant matches between NFlGRP domains and the other proteins generally correlated with the 
homology blocks previously defined by multiple alignment analyses (Refs. (3,63)). Retrieval codes for the sequences cited in this table refer 
to the NBRF/PIR database and are as follows: A30135 for IRAl, A35656 for IRA2, and SO1966 for bovine GAP. The N-terminal, GAP-re- 
lated, and C-terminal domains of NFlGRP correspond to residues l-1132,1133-1537, and 1538-2818, respectively, of the protein. 
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(Buchberg et aZ., 1990; Xu et aZ., 1990a) revealed ho- 
mology to the mammalian GAP protein and yeast 
IRA1 and IRA2 gene products, which modulate the 
activity of the p21 ras protein in their respective hosts 
by accelerating the rate at which ras hydrolyzes GTP 
to become inactive ra.s-GDP. This provided the first 
glimpse of the function of NFl; like GAP, it may be an 
upstream regulatory protein for ro.s (or a ras-related 
protein) with its normal function being to down-regu- 
late one or more members of the ras family involved in 
mitogenic signal transduction. This model received 
further support when it was shown that the proposed 
GAP-related domain of NFl (NFI-GRD) could com- 
plement loss of IRA function in yeast, and that it 
could stimulate ras-GTPase activity in uiuo and in 
vitro (Ballester et al., 1990; Martin et aZ., 1990; Xu et 
al:, 1990b). We propose that the NFl gene product be 
named the NF1-GAP-related protein (NFlGRP; 
Gutmann et al., 1991). 
An alternate model of ras-NFlGRP interaction 
postulates that NFlGRP may instead (or in addition) 
be a downstream effector for ras. A downstream 
model has also been proposed for the related GAP. 
Mutations in the putative rus effector domain inacti- 
vate the transforming ability of ras and block GTPase 
activation by GAP, yet retain guanine nucleotide 
binding capacity (Adari et al., 1988; Cales et al., 1988). 
NFl -GRD interactions with effector and oncogenic 
mutants of m-s have shown similar results, suggesting 
that NFlGRP may also interact with ros p21 through 
its effector domain and be a target of activated ra 
(Martin et aZ., 1990; Xu et al., 1990b; Bollag and 
McCormick, 1991). It should be cautioned, however, 
that none of these studies were done using full-length 
NFlGRP. 
Nonetheless, the downstream effector model is at- 
tractive for its ability to account for the role of ras in 
certain cells of neuroectodermal origin. In the rat 
pheochromocytoma cell line PC12, activated ras in- 
duces differentiation and blocks proliferation (Bar- 
Sagi and Feramisco, 1985; Noda et uZ., 1985). Inhibi- 
tion of ras in these cells blocks neural differentiation 
normally induced by nerve growth factor (Hagag et 
al., 1986; Szeberenyi et al., 1990). Activated ras has 
also been shown to induce cell cycle arrest when intro- 
duced into rat Schwann cells (Ridley et cd., 1988). 
This is significant because Schwann cells may be the 
original cells that recruit other cell types in the for- 
mation of neurofibromas and neurofibrosarcomas 
(Ratner et uZ., 1990; Sheela et al., 1990). Therefore, if 
NFlGRP is the target (effector) of ras, then loss of 
NFlGRP function could lead to a block of normal 
differentiation resulting in unrestrained proliferation 
of Schwann cells. 
Either of these two models, with NFlGRP as the 
upstream negative regulator or downstream effector, 
are consistent with NFl being a tumor suppressor 
gene, where the phenotype results from the loss of 
both alleles of the gene (Knudson, 1985). Previous 
studies of NFl tumors did not show a consistent loss 
of heterozygosity for NFl in 17q11.2 (Skuse et al., 
1989; Menon et al., 1990; Glover et al., 1991), but these 
interpretations were made difficult by frequent losses 
on 17p, apparently reflecting the major role that loss 
of the ~53 gene plays in tumor progression in this 
disorder (Nigro et al., 1989; Menon et al., 1990). More 
recent analyses have indicated that loss of heterozy- 
gosity involving only 17q can be demonstrated at least 
for some tumors (Skuse, 1990; E. Legius and T. 
Glover, personal communication; B. Ponder, personal 
communication). 
The large NFl transcript and 300-kb gene size rep- 
resent a large target for mutations. Assuming that the 
NFl phenotype results from loss of function muta- 
tions, causative mutations may be dispersed through- 
out the coding and regulatory region. In the patients 
surveyed thus far, this seems to be the case (Cawthon 
et al., 1990a; Wallace et al., 1990; M. Wallace et al., 
unpublished observations). The size of the gene alone, 
however, cannot fully account for the high mutation 
rate. At best, the possible target size is only a factor of 
10 larger than other genes, whereas the mutation rate 
is about loo-fold higher than the usual rate for a sin- 
gle locus. There is presently not enough mutation 
data to determine whether there is a mutational hot 
spot within this region. 
The complete sequence of the NFl gene product 
has provided few additional clues to its function. The 
lack of SH2 and SH3 domains are in contrast to GAP. 
Homologous to noncatalytic regions of the oncogene 
src, these domains are thought to direct interactions 
with phosphotyrosine proteins involved in signal 
transduction (Koch et al., 1991). Their absence in 
NFlGRP implies that NFlGRP and GAP are not in- 
terchangeable in the cell, and that NFlGRP is proba- 
bly not directly modulated through tyrosine phos- 
phorylation by activated growth factor receptors. The 
potential sites for tyrosine and serinelthreonine 
phosphorylation (Fig. 4) may mean that an interme- 
diate between the activated receptor and NFlGRP 
may modulate its activity, since there is evidence that 
NFlGRP is phosphorylated on serine and threonine 
residues (J. Downward, personal communication). A 
potential candidate for this intermediate could be one 
of the members of the ERK family, which are acti- 
vated by tyrosine phosphorylation by nerve growth 
factor and are themselves serine/threonine protein ki- 
nases (Boulton et al., 1991). Certainly, the large size of 
the product in relation to the small portion conferring 
GAP activity indicates that other domains may be 
involved in modulating the ras-GTPase activity of 
this protein, or carrying out entirely different func- 
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tions. The sequence homology with yeast IRA1 and 
IRA2 (Table 1) extends beyond the GAP catalytic do- 
main toward both termini, with strong homology in 
the carboxy terminus. The homology, both globally 
and within each domain, is most significant with the 
IRA2 protein. There may be therefore more extensive 
functional homology with these members of the GAP 
family than with GAP itself. It may be useful to think 
of the NFlGRP as consisting of three domains; an 
amino-terminus of unknown function, a GAP-related 
middle domain, and a carboxy-terminus related to the 
IRA2 and IRA1 gene products. Unfortunately, the 
functions of these domains of the IRA gene products 
are not known even in this simple eukaryote. For 
NFlGRP, interaction with other factors in the path- 
way leading to differentiation, such as the low-affin- 
ity nerve growth factor receptor and the trk oncogene 
product, or factors that mediate between these and 
NFlGRP, may be localized to these yet undefined re- 
gions. Interactions at these other domains may also 
ultimately provide a clue as to the reasons why a mu- 
tation in a ubiquitously expressed gene reveals its 
character predominantly in cells derived from the em- 
bryonic neural crest. 
It is presently unclear how the alternatively spliced 
transcripts and the corresponding protein isoforms 
play their unique role in NFlGRP function. We have 
not yet conducted an exhaustive search of the tissues 
where each of these transcripts can be found. We 
know that at least in some tissues, however, their ex- 
pression is not mutually exclusive. These alternative 
forms may play a role in the diverse clinical manifes- 
tations of the disorder. Germline mutations in some 
of the alternatively spliced exons may give rise to 
some of the more unusual NFl phenotypes. 
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